Sean Lavin

Shares of medical technology company Medtronic PLC (NYSE: MDT) were flirting with the $100 per share mark for parts of 2018, but have since come down to a level that should be taken advantage of by investors, according to BTIG. The Analyst Analyst Sean Lavin upgraded Medtronic from...

Transenterix Inc (NYSE: TRXC) shares have spiked 50 percent in the last week, 71 percent in the last month and 734 percent in the last year. But one analyst senses diminishing momentum. The Rating BTIG analyst Sean Lavin downgraded TransEnterix to Neutral and withdrew his price target. The...

After doubling in value over the past seven months alone, shares of Tactile Systems Technology Inc (NASDAQ: TCMD) are trading at a "stretched" valuation despite expectations for continued growth ahead, according to BTIG. The Analyst BTIG's Sean Lavin downgraded Tactile Systems...

The 35-percent sell-off in shares of EXACT Sciences Corporation (NASDAQ: EXAS) offer an attractive entry point, according to BTIG Research.  The molecular diagnostics product company's main product is Cologuard, which is used to detect colorectal cancer. The Analyst Analyst Sean...

After a strong run that sent shares of Insulet Corporation (NASDAQ: PODD) up 50 percent over the last year, BTIG analyst Sean Lavin finally sees shares as fairly valued. This pushed him to downgrade Insulet to a Neutral rating. “We do not feel a reasonable revenue multiple would provide us...

Endologix, Inc. (NASDAQ: ELGX) announced on Thursday after the market close that it needs to conduct a confirmatory clinical trial for its Nellix Endovascular Aneurysm Sealing System with the previously updated instructions for use and the Gen2 device design. This follows the company's meeting...

Shares of Insulet Corporation (NASDAQ: PODD) responded positively to the company’s solid results and guidance. The current share price reflects optimism around a Medicare coverage decision and could decline if the decision does not come soon, BTIG’s Sean Lavin said in a report. He...

Over the past year, the gap between MedTech stocks and the S&P index has narrowed significantly, and these are currently trading near parity as compared to the ~12 percent premium at which MedTech names traded a year earlier, BTIG’s Sean Lavin said in a report. MedTech stocks have been...

BTIG’s Sean Lavin sees Organovo Holdings Inc (NASDAQ: ONVO) as a long-term investment “with multiple opportunities”. Lavin initiated coverage of the company with a Buy rating and price target of $5. Multiple Opportunities The analyst mentioned that the markets for liver and kidney...

The quiet period surrounding Irhythm Technologies Inc (NASDAQ: IRTC)'s stock has now ended after its fantastic IPO debut, so research firms are free to now evaluate the stock and issue their opinions. Here is a summary of some of the research reports, which were made available for the first time on...

BTIG cut DexCom, Inc. (NASDAQ: DXCM) to Neutral from Buy, as the shares have reached its $92 price target. The firm added that the company must focus on profitability "for a sustained run well above $100." "While we do not think shares are overvalued and could argue for a bit more upside as revenue...

Although BTIG’s Sean Lavin sees the current valuation of NeoGenomics, Inc. (NASDAQ: NEO) shares as fair, there do not appear to be sufficient near-term catalysts to drive any significant upside to the stock. Lavin downgraded the rating on the company from Buy to Hold. Limited Upside “...

EXACT Sciences Corporation (NASDAQ: EXAS) shares spiked 34 percent on Tuesday, following a JAMA [The Journal of the American Medical Association] article meant for release on June 21 being leaked. BTIG’s Sean Lavin maintained a Buy rating for the company, with a $9 price target. The analyst...